TriangleCD19x22 CAR T (NCT06559189)
CD19x22 CAR T trial for B-cell Acute Lymphoblastic Leukemia (NCT06559189). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Most children with B-cell leukemia are cured. For those who relapse twice, or relapse after transplant, or after CAR T therapy, the path narrows quickly.
The idea: a CAR T cell that recognizes two leukemia markers at once, built for children.
CD19 CAR T cells can fail when the leukemia stops displaying CD19. At Children's Hospital Colorado, a child's own T cells receive a receptor that binds both CD19 and CD22, so the leukemia has to lose both to escape. The cells are made in the university's own manufacturing facility, and given once after chemotherapy makes room.
Heavy and light disease are studied in parallel, from three months to age thirty, with careful dose escalation. Vanessa Fabrizio leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.